Study Title
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Study Number
S2013
Enrollment status
Open
Categories
Cancer Control/Symptom Management
Study Summary
This study examines how certain risk factors (such as age, sex, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Study Coordinator(s)
- Navigator Courtney, 309-243-3660 cbrown@illinoiscancercare.com
- Erica, 309-243-3626 eraynor@illinoiscancercare.com
- Jess, 309-243-3603 jcallais@illinoiscancercare.com
Study Link
View Study DetailsAdditional Information
Peoria, Bloomington, Galesburg, Pekin, Washington